Contact Us marketing@medicilon.com
CN
×
Close Button

FAQs

FAQs
What is Stability of a Drug?
The stability of a drug refers to the degree to which the physical, chemical, biological and microbial properties of an active substance or formulation can be maintained within prescribed limits during its entire storage and use.
Learn more
Preclinical Safety Characteristics of siRNA Drugs
The biological effects of silencing of target mRNA may be present, but other effects are not easily observable.
Learn more
What are the Advantages and Disadvantages of Nucleic Acid Drugs?
Advantages: Short development cycle, fast target screening; A wide range of treatment areas; Resistant to drug resistance; Long-lasting effect; High success rate of R&D
Learn more
What are Polymorphs?
In July 2007, the United States FDA issued technical guidelines for generic drug crystal research, clarifying that polymorph includes crystals, amorphous forms, as well as solvates and hydrates.
Learn more
Why is sample purity required for screening API crystal structures?
Impurities can affect the dynamic stability of APIs in solution and suspension by affecting nucleation and growth rates.
Learn more
Can Medicilon Complete Preclinical DMPK Services?
Can Medicilon complete preclinical DMPK services?
Learn more
What are the Preclinical PK Data Analysis Methods?
What are the preclinical PK data analysis methods?
Learn more
What In Vivo PK Tests Should be Completed Before IND Filing in China?
What In Vivo PK tests should be completed before IND filing in China?
Learn more
What Should be Done for Significant AUC Differences In Vivo PK Tests in Animals?
(1) The reasons for large differences can be summarized as poor solubility of the compound or solubility being subject to significant fluctuations in digestive tract pH. (2) Improve the formulation and adjust the digestive tract PH value.
Learn more
What Should Explain Bioavailability F > 100% in Animals' In Vivo PK Test?
(1) Dose deviation due to administration error. (2) Non-linear PK. (3) High bioavailability and individual variability in the DMPK properties of the drug, with IV and PO, given to different groups of animals.
Learn more